Harbor Health Care ETF (MEDI)

Built on a rich history of Health Care Investing

NAV as of 11/5/2026
$34.82
NAV Daily Change
-$1.44 ↓
NAV YTD Return
10.79% ↑
Net Expense Ratio (%)
0.80
Total Net Assets (million) as of 11/6/2026
$41.785
Benchmark
Russell 3000® Growth Health Care Index

Why Invest in MEDI?

Health care costs have increased over time, while forecasts signal continued upward trend looking ahead. A broader shift towards value‑based approaches within health care is likely needed, with emphasis on lower costs of care and improved patient outcomes. This may enable opportunities for health care companies best positioned to facilitate transition towards value over quantity.

In addition, health care is home to other disruptive themes such as targeted oncology, liquid biopsy, gene therapy, orphan diseases, and others that may represent compelling long‑term growth opportunities.

The investment team behind MEDI seeks to construct a portfolio capable of benefiting from the secular growth and innovation of the U.S. health care system, while achieving alpha relative to the broader Health Care sector by investing in quality businesses with differentiated products, technologies, and services which meet the team's disciplined valuation criteria.

Westfield Capital Management
Investment team
Harbor Capital Advisors, Inc.
Learn more

As of 11/5/2026

$34.82

Price (NAV)

-$1.44

NAV Daily Change ($)

-3.97%

NAV Daily Change (%)

10.79%

NAV YTD Return

As of 11/5/2026

11/16/2022

Inception Date

0.80

Expense Ratio (%)

$41.785

Total Net Assets (million)

1,200,000

Shares Outstanding
(As of 11/6/2026)

MEDI

Ticker

41151J869

Cusip

NYSE Arca

Exchange

US41151J896

ISIN

Foreside Fund Services, LLC

Distributor

Annually

Dividend Frequency

Health

Morningstar Category

Russell 3000® Growth Health Care Index

Benchmark

1,310,365

Implied Liquidity™ (Shares)

$47,518,553.52

Implied Liquidity

Investment Objective:

The Fund seeks long-term growth of capital.

As of 11/4/2026

$36.11

Bid/Ask Mid Price

$35.72

Closing Market Price

-$0.16

Premium/Discount ($)

-0.44%

Premium/Discount (%)
2025
Q1 2026
Q2 2026
Q3 2026
Q4 2026
YTD
Days Traded at a Premium
186
7
5
4
3
19
Days Traded at a Discount
64
54
57
60
22
193

0.21%

30-Day Median Bid/Ask Spread

6,338

Exchange Volume (Shares)

USD

Trading Currency

Historical Premium Discount to NAV

No Data Available

Health care is a sector that we are very passionate about, and one in which we have a strong history.

Matthew R. Renna

Partner, Portfolio Manager, Westfield Capital Management Company L.P.

Performance

Select an option

Loading Performance Data...

3 Mo.
YTD Return
1 Yr.
3 Yr.
Since Fund Inception
Net Expense Ratio
Gross Expense Ratio
Health Care ETF - at NAV
-3.34%
4.04%
14.89%
14.98%
14.52%
0.80%
0.80%
Market Price
-3.25%
4.10%
14.91%
15.07%
14.75%
--
--
Russell 3000 Growth Health Care Index
0.28%
5.19%
22.77%
14.12%
12.22%
--
--

Performance data shown represents past performance and is no guarantee of future results. Fund performance is net of management fees and expenses and reflects reinvested dividends and distributions. Past performance reflects the beneficial effect of any expense waivers or reimbursements, without which returns would have been lower. Investment returns and principal value will fluctuate and when redeemed may be worth more or less than their original cost. Returns for periods less than one year are not annualized. Current performance may be higher or lower and is available through the most recent month end at harborcapital.com or by calling 800-422-1050.

The Russell 3000® Growth Health Care Index is an unmanaged index generally representative of companies involved in medical services or health care in the Russell 3000 Index, which is comprised of the 3,000 largest U.S. companies as determined by total market capitalization. This unmanaged index does not reflect fees and expenses and is not available for direct investment.

Select an option

Ex-Date
Record Date
Payable Date
Ordinary Income
Short Term Capital Gains
Long Term Capital Gains
Total Distribution
12/18/2025
12/18/2025
12/23/2025
0.01246
--
0.06269
0.07515
12/19/2024
12/19/2024
12/25/2024
0.09709
--
0.03746
0.13455
12/20/2023
12/21/2023
12/26/2023
0.16429
0.29701
--
0.46130
12/20/2022
12/21/2022
12/26/2022
--
--
--
0.00000

Holdings

As of 10/31/2026

45

Number of Holdings

338379.5

Wtd Avg Market Cap ($Mil)

10.05

Price/Book Ratio

37

Adjusted Trailing P/E Ratio

28.2

% EPS Growth - Past 3 Yr

-14.32

Return on Equity (%)

31.3

Forecasted P/E Ratio

As of 11/4/2026

Company Name [Ticker]
% of Net Assets
ELI LILLY & CO[LLY]
20.9
ASCENDIS PHARMA A/S[ASND]
16.2
ARGENX SE - ADR[ARGX]
4.8
RHYTHM PHARMACEUTICALS INC[RYTM]
3.7
VAXCYTE INC[PCVX]
3.5
GUARDANT HEALTH INC[GH]
3.2
INSMED INC[INSM]
2.9
REVOLUTION MEDICINES INC[RVMD]
2.6
IDEXX LABORATORIES INC[IDXX]
2.5
UNITED THERAPEUTICS CORP[UTHR]
2.3
% of Total Holdings:
62.6%

This information should not be considered as a recommendation to purchase or sell a particular security. The weightings, holdings, industry, sector and/or countries mentioned may change at any time and may not represent current or future investments.

As of 11/4/2026

Company Name [Ticker]
Category Name
Country
Cusip
Shares
Current Price ($)
Market Value ($)
% of Net Assets
ELI LILLY & CO [LLY]
EQUITY
532457108
6,941
1,417.99
9,842,268.59
20.9
ASCENDIS PHARMA A/S [ASND]
EQUITY
04351P101
29,663
257.93
7,650,977.59
16.2
ARGENX SE - ADR [ARGX]
EQUITY
04016X101
2,426
931.38
2,259,527.88
4.8
RHYTHM PHARMACEUTICALS INC [RYTM]
EQUITY
76243J105
15,656
110.68
1,732,806.08
3.7
VAXCYTE INC [PCVX]
EQUITY
92243G108
25,027
65.68
1,643,773.36
3.5
GUARDANT HEALTH INC [GH]
EQUITY
40131M109
8,858
168.58
1,493,281.64
3.2
INSMED INC [INSM]
EQUITY
457669307
12,321
110.00
1,355,310.00
2.9
REVOLUTION MEDICINES INC [RVMD]
EQUITY
76155X100
6,105
199.70
1,219,168.50
2.6
IDEXX LABORATORIES INC [IDXX]
EQUITY
45168D104
1,691
698.55
1,181,248.05
2.5
UNITED THERAPEUTICS CORP [UTHR]
EQUITY
91307C102
1,770
608.49
1,077,027.30
2.3
CENCORA INC [COR]
EQUITY
03073E105
2,904
354.00
1,028,016.00
2.2
NATERA INC [NTRA]
EQUITY
632307104
2,462
391.03
962,715.86
2.0
UNITEDHEALTH GROUP INC [UNH]
EQUITY
91324P102
1,981
409.38
810,981.78
1.7
INTUITIVE SURGICAL INC [ISRG]
EQUITY
46120E602
1,634
482.10
787,751.40
1.7
HEALTHEQUITY INC [HQY]
EQUITY
42226A107
7,070
108.84
769,498.80
1.6
ABBVIE INC [ABBV]
EQUITY
00287Y109
2,567
294.83
756,828.61
1.6
ABIVAX SA-ADR [ABVX]
EQUITY
00370M103
8,217
89.49
735,339.33
1.6
PTC THERAPEUTICS INC [PTCT]
EQUITY
69366J200
10,539
68.97
726,874.83
1.5
SUPERNUS INC [SUPN]
EQUITY
45579U109
24,186
28.21
682,287.06
1.4
MCKESSON CORP [MCK]
EQUITY
58155Q103
632
1,069.44
675,886.08
1.4
DANAHER CORP [DHR]
EQUITY
235851102
2,680
234.93
629,612.40
1.3
GLAUKOS CORP [GKOS]
EQUITY
377322102
2,386
246.70
588,626.20
1.2
LEGEND BIOTECH CORP-ADR [LEGN]
EQUITY
52490G102
25,815
22.77
587,807.55
1.2
XENON PHARMACEUTICALS INC [XENE]
EQUITY
98420N105
14,255
39.19
558,653.45
1.2
IRHYTHM HOLDINGS INC [IRTC]
EQUITY
450056106
3,824
134.00
512,416.00
1.1
VERTEX PHARMACEUTICALS INC [VRTX]
EQUITY
92532F100
868
549.04
476,566.72
1.0
AXSOME THERAPEUTICS INC [AXSM]
EQUITY
05464T104
3,085
137.00
422,645.00
0.9
RADNET INC [RDNT]
EQUITY
750491102
5,247
80.26
421,124.22
0.9
IONIS PHARMACEUTICALS INC [IONS]
EQUITY
462222100
10,222
40.15
410,413.30
0.9
VIATRIS INC [VTRS]
EQUITY
92556V106
20,293
19.22
390,031.46
0.8
PRAXIS PRECISION MEDICINES I [PRAX]
EQUITY
74006W207
1,245
284.79
354,563.55
0.8
ENLIVEN THERAPEUTICS INC [ELVN]
EQUITY
29337E102
7,402
47.25
349,744.50
0.7
TANGO THERAPEUTICS INC [TNGX]
EQUITY
87583X109
14,951
23.18
346,564.18
0.7
ORUKA THERAPEUTICS INC [ORKA]
EQUITY
687604108
3,337
101.41
338,405.17
0.7
SPYRE THERAPEUTICS INC [SYRE]
EQUITY
00773J202
3,402
99.04
336,934.08
0.7
RELAY THERAPEUTICS INC [RLAY]
EQUITY
75943R102
14,314
18.03
258,081.42
0.5
PALVELLA THERAPEUTICS INC [PVLA]
EQUITY
697947109
1,545
162.28
250,722.60
0.5
BRIGHTSPRING HEALTH SERVICES [BTSG]
EQUITY
10950A106
3,320
68.455
227,269.94
0.5
KRYSTAL BIOTECH INC [KRYS]
EQUITY
501147102
695
310.84
216,033.80
0.5
ADAPTIVE BIOTECHNOLOGIES [ADPT]
EQUITY
00650F109
7,770
26.71
207,536.70
0.4
10X GENOMICS INC-CLASS A [TXG]
EQUITY
88025U109
3,066
67.52
207,016.32
0.4
SOPHIA GENETICS SA [SOPH]
EQUITY
H82027105
24,743
6.97
172,458.71
0.4
HEALTH CATALYST INC [HCAT]
EQUITY
42225T107
95,073
1.59
151,166.07
0.3
INVENTIVA SA - ADR [IVA]
EQUITY
46124U107
34,663
3.87
134,145.81
0.3
Total
--
--
--
--
--
45,940,107.89
97.2
Cash and Other Assets Less Liabilities
--
--
--
--
--
--
2.8
Total Net Assets
--
--
--
--
--
--
100.0

As of 10/31/2026

Sector Breakdown

Health Care

MEDI

97.2%

Benchmark

99.8%

Cash

MEDI

2.8%

Benchmark

0.0%

Consumer Discretionary

MEDI

0.0%

Benchmark

0.1%

Consumer Staples

MEDI

0.0%

Benchmark

<0.1%

Industrials

MEDI

0.0%

Benchmark

<0.1%

MEDI: Health Care ETF

Benchmark: Russell 3000 Growth Health Care Index

As of 10/31/2026

Economic Sector
Health Care ETF %
Russell 3000 Growth Health Care Index %

Health Care

9.5
15.0

Industrials

--
7.9

Consumer Discretionary

--
-7.8

Consumer Staples

--
-31.5

Investment Team

Westfield Capital Management

Westfield Capital Management Company, L.P. is dedicated to providing strong and consistent investment performance based on a disciplined, team‑based approach, with exceptional client service. Westfield believes their greatest strength comes from the collective wisdom of a fully engaged and inspired team working together with clear objectives. Additionally, Westfield embraces their partnership structure, which aligns the advancement of the organization with their clients and serves to attract and retain exceptional talent.

Important Information

Investing involves risk, principal loss is possible. Unlike mutual funds, ETFs may trade at a premium or discount to their net asset value.

Shares are bought and sold at market price not net asset value (NAV). Market price returns are based upon the closing composite market price and do not represent the returns you would receive if you traded shares at other times.

There is no guarantee that the investment objective of the Fund will be achieved.  Stock markets are volatile and equity values can decline significantly in response to adverse issuer, political, regulatory, market and economic conditions. Since the Fund may hold foreign securities, it may be subject to greater risks than funds invested only in the U.S. These risks are more severe for securities of issuers in emerging market regions. Foreign currencies can decline in value and can adversely affect the dollar value of the fund. Since the Fund typically invests in a limited number of companies, an adverse event affecting a particular company may hurt the Fund's performance more than if it had invested in a larger number of companies. Health Care Industry Risk: Because the Fund seeks to invest all, or substantially all, of its assets in the health care industry, the value of its shares will depend on the general condition of the that industry. The health care industry may be affected by any number of factors, including, but not limited to, lapsing patent protection, industry innovation, extensive government regulation, restrictions on government reimbursement for medical expenses, research and development costs, limited product lines, product liability litigation, an increased emphasis on outpatient services, and competitive forces. Authorized Participant Concentration/Trading Risk: Only authorized participants ("APs") may engage in creation or redemption transactions directly with the Fund. The Fund is classified as non‑diversified, a non‑diversified Fund may invest a greater percentage of its assets in securities of a single issuer, and/or invest in a relatively small number of issuers, it is more susceptible to risks associated with a single economic, political or regulatory occurrence than a more diversified portfolio. New Fund Risk: There can be no assurance that the Fund will grow to or maintain an economically viable size, in which case the Board of Trustees may determine to liquidate the Fund. Small and Mid Cap Risk: The Fund's performance may be more volatile because it may invest in issuers that are smaller companies.

The views expressed herein may not be reflective of current opinions, are subject to change without prior notice, and should not be considered investment advice.

Weighted Average Market Capitalization: The average size of the companies in a portfolio or index as measured by the market value of outstanding shares.

Price/Book: The price‑to‑book (P/B) ratio evaluates a firm's market value relative to its book value.

Adjusted Trailing P/E Ratio: The Adjusted Trailing P/E (Price/Earnings) Ratio is the closing stock price divided by the sum of the last 12 months actual EPS.

% EPS Growth – Past 3 year: Earnings per share refers to the bottom‑line measure of a company’s profitability defined as net income divided by the number of outstanding shares.

Return on Equity: Return on equity (ROE) is a measure of financial performance calculated by dividing net income by shareholders' equity.

Forecasted P/E Ratio: a measure of the P/E (price‑to‑earnings) ratio using forecasted earnings for the P/E calculation.

Bid/Ask Mid Price: the midpoint between the highest bid and the lowest offer, as of the time that the Fund’s NAV is calculated, typically 4 p.m. Eastern Time.

Premium/Discount ($): the difference between the Fund’s market price and NAV, expressed as a percentage of NAV. A premium is the amount that the Fund is trading above the reported NAV. A discount is the amount that the Fund is trading below the reported NAV.

30‑Day Median Bid/Ask Spread: calculated by identifying national best bid and national best offer ("NBBO") for each fund as of the end of each 10 second interval during each trading day of the last 30 calendar days and dividing the difference between each such bid and offer by the midpoint of the NBBO. The median of those values is identified and that value is expressed as a percentage (rounded to the nearest hundredth).

Alpha is the risk‑adjusted excess return of an investment relative to the return of a benchmark index.